Literature DB >> 10794803

New drugs and novel targets for treatment of invasive fungal infections in patients with cancer.

C C Chiou1, A H Groll, T J Walsh.   

Abstract

Invasive fungal infections have emerged as important causes of morbidity and mortality in profoundly immunocompromised patients with cancer. Current treatment strategies for these infections are limited by antifungal resistance, toxicity, drug interactions, and expense. In order to overcome these limitations, new antifungal compounds are being developed, which may improve our therapeutic armamentarium for prevention and treatment of invasive mycoses in high-risk patients with neoplastic diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794803     DOI: 10.1634/theoncologist.5-2-120

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  18 in total

Review 1.  Voriconazole: in the treatment of invasive aspergillosis.

Authors:  Richard B R Muijsers; Karen L Goa; Lesley J Scott
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

Review 3.  [Anti-fungal drugs. Current status and guidelines for their administration].

Authors:  Rodrigo Fernández Alonso; Maria Esther González García; Joaquín Fernández García; Francisco Javier Cepeda Piorno
Journal:  Clin Transl Oncol       Date:  2005-10       Impact factor: 3.405

4.  Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  K Yoshikawa; Y Nakazawa; Y Katsuyama; K Hirabayashi; S Saito; T Shigemura; M Tanaka; R Yanagisawa; K Sakashita; K Koike
Journal:  Infection       Date:  2014-02-25       Impact factor: 3.553

5.  Amentoflavone stimulates mitochondrial dysfunction and induces apoptotic cell death in Candida albicans.

Authors:  In-Sok Hwang; Juneyoung Lee; Hong-Guang Jin; Eun-Rhan Woo; Dong Gun Lee
Journal:  Mycopathologia       Date:  2011-12-31       Impact factor: 2.574

6.  Caspofungin.

Authors:  G M Keating; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Antifungal research strategies aiming for new targets.

Authors:  Glorivee Pagán-Mercado; Marielis E Rivera-Ruiz; Frances Segarra-Román; José R Rodríguez-Medina
Journal:  P R Health Sci J       Date:  2009-09       Impact factor: 0.705

Review 8.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience.

Authors:  Simone Cesaro; Liliana Strugo; Rita Alaggio; Giovanni Cecchetto; Luca Rigobello; Marta Pillon; Riccardo Cusinato; Luigi Zanesco
Journal:  Support Care Cancer       Date:  2003-09-13       Impact factor: 3.603

10.  Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Authors:  Thomas J Walsh; Mats O Karlsson; Timothy Driscoll; Adriano G Arguedas; Peter Adamson; Xavier Saez-Llorens; Ajay J Vora; Antonio C Arrieta; Jeffrey Blumer; Irja Lutsar; Peter Milligan; Nolan Wood
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.